RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
05 Aprile 2024 - 2:30PM
Business Wire
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:
RNXT), a clinical-stage biopharmaceutical company developing
novel precision oncology therapies based on a local drug-delivery
platform, today announced that Shaun Bagai, RenovoRx’s Chief
Executive Officer, will present at the Canaccord Genuity 2024
Horizons in Oncology Virtual Conference to be held on April 15,
2024.
Mr. Bagai will meet with investors and participate in a panel
discussion hosted by Bill Maughan, Senior Analyst at Canaccord
Genuity. The panel is titled “Delivering High Local Concentrations
of Chemotherapy for Solid Tumors,” and takes place on Monday, April
15, 2024, at 8:00 am ET. He will discuss the initial positive
interim analysis in the Company’s pivotal Phase III TIGeR-PaC
clinical trial. The study is evaluating the Company’s lead product
candidate, RenovoGem™, and proprietary Trans-Arterial
Micro-Perfusion (TAMP™) therapy platform for the
treatment of locally advanced pancreatic cancer.
Mr. Bagai will also discuss the Company’s plans for 2024 and
beyond as well as recent milestones, including the completion of a
private placement in January 2024. The private placement extended
cash runway, allowing the Company to advance towards its near-term
key milestone of a second interim analysis for TIGeR-PaC that will
be triggered by the 52nd event (death), which is estimated to occur
in late 2024.
CG 2024 Horizons in Oncology Virtual
Conference Date: April 15, 2024 Time:
8:00am ET – 8:50am ET Speaker: Shaun Bagai, CEO
Location: Virtual
To schedule a one-on-one investor meeting with Mr. Bagai, please
contact your Canaccord representative or KCSA Strategic
Communications at RenovoRx@KCSA.com.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company
developing proprietary targeted combination therapies for high
unmet medical need with a goal to improve therapeutic outcomes for
cancer patients undergoing treatment. RenovoRx’s patented
Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is
designed to ensure precise therapeutic delivery to directly target
the tumor while potentially minimizing a therapy’s toxicities
versus systemic intravenous therapy. RenovoRx’s novel and patented
approach to targeted treatment offers the potential for increased
safety, tolerance, and improved efficacy. Our Phase III lead
product candidate, RenovoGemTM, a novel oncology drug-device
combination product, is being investigated under a U.S.
investigational new drug application that is regulated by the FDA’s
21 CFR 312 pathway. RenovoGem is currently being evaluated for the
treatment of locally advanced pancreatic cancer by the Center for
Drug Evaluation and Research (the drug division of FDA.)
RenovoRx is committed to transforming the lives of patients by
delivering innovative solutions to change the current paradigm of
cancer care. RenovoGem is currently under investigation for TAMP
therapeutic delivery of gemcitabine and has not been approved for
commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on
Facebook, LinkedIn, and Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release, the conference presentation described
herein, and statements of the Company’s management made in
connection therewith contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934, including but not
limited to statements regarding (i) our clinical trials and
studies, including anticipated timing, statements regarding the
potential of RenovoCath®, RenovoGem™ or TAMP™ or regarding our
ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the
potential for our product candidates to treat or provide clinically
meaningful outcomes for certain medical conditions or diseases and
(iii) our efforts to expand our intellectual property. Statements
that are not purely historical are forward-looking statements. The
forward-looking statements contained herein are based upon our
current expectations and beliefs regarding future events, many of
which, by their nature, are inherently uncertain, outside of our
control and involve assumptions that may never materialize or may
prove to be incorrect. These may include estimates, projections and
statements relating to our research and development plans,
intellectual property development, clinical trials, our therapy
platform, business plans, financing plans, objectives and expected
operating results, which are based on current expectations and
assumptions that are subject to known and unknown risks and
uncertainties that may cause actual results to differ materially
and adversely from those expressed or implied by these
forward-looking statements. These statements may be identified
using words such as “may,” “expects,” “plans,” “aims,”
“anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and
“potential,” or the negative of these terms or other comparable
terminology regarding RenovoRx’s expectations strategy, plans or
intentions, although not all forward-looking statements contain
these words. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, that could cause
actual events to differ materially from those projected or
indicated by such statements, including, among other things: (i)
the risk that the Company’s participation in the conference
described herein will not lead to any benefits for the Company;
(ii) circumstances which would adversely impact our ability to
efficiently utilize our cash resources on hand or raise additional
funding, (iii) the timing of the initiation, progress and potential
results (including the results of interim analyses) of our
preclinical studies, clinical trials and our research programs;
(iv) the possibility that interim results may not be predictive of
the outcome of our clinical trials, which may not demonstrate
sufficient safety and efficacy to support regulatory approval of
our product candidate, (v) that the applicable regulatory
authorities may disagree with our interpretation of the data;
research and clinical development plans and timelines, and the
regulatory process for our product candidates; (vi) future
potential regulatory milestones for our product candidates,
including those related to current and planned clinical studies;
(vii) our ability to use and expand our therapy platform to build a
pipeline of product candidates; (viii) our ability to advance
product candidates into, and successfully complete, clinical
trials; (ix) the timing or likelihood of regulatory filings and
approvals; (x) our estimates of the number of patients who suffer
from the diseases we are targeting and the number of patients that
may enroll in our clinical trials; (xi) the commercialization
potential of our product candidates, if approved; (xii) our ability
and the potential to successfully manufacture and supply our
product candidates for clinical trials and for commercial use, if
approved; (xiii) future strategic arrangements and/or
collaborations and the potential benefits of such arrangements;
(xiv) our estimates regarding expenses, future revenue, capital
requirements and needs for additional financing and our ability to
obtain additional capital; (xv) the sufficiency of our existing
cash and cash equivalents to fund our future operating expenses and
capital expenditure requirements; (xvi) our ability to retain the
continued service of our key personnel and to identify, and hire
and retain additional qualified personnel; (xvii) the
implementation of our strategic plans for our business and product
candidates; (xviii) the scope of protection we are able to
establish and maintain for intellectual property rights, including
our therapy platform, product candidates and research programs;
(xix) our ability to contract with third-party suppliers and
manufacturers and their ability to perform adequately; (xx) the
pricing, coverage and reimbursement of our product candidates, if
approved; and (xxi) developments relating to our competitors and
our industry, including competing product candidates and therapies.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in documents that we
file from time to time with the Securities and Exchange
Commission.
Forward-looking statements included herein are made as of the
date hereof, and RenovoRx does not undertake any obligation to
update publicly such forward-looking statements to reflect
subsequent events or circumstances, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240405398904/en/
KCSA Strategic Communications Valter Pinto, Managing Director
T:212-896-1254 renovorx@kcsa.com
Grafico Azioni RenovoRx (NASDAQ:RNXT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni RenovoRx (NASDAQ:RNXT)
Storico
Da Giu 2023 a Giu 2024